Discover your next big idea for life sciences at PACK EXPO Las Vegas
Experience a breakthrough in life sciences packaging—explore solutions from 2,300 suppliers spanning all industries, all in one place this September

FDA’s Aduhelm Approval Process was Problematic

Biogen was prepared to spend more than two-and-a-half times the cost of the drug’s development on marketing.

Download
Getty Images

According to a recent New York Times article, a congressional investigation into the FDA’s approval of Alzheimer’s drug Aduhelm was “rife with irregularities.” The 18-month investigation was initiated by two congressional committees after the drug was approved. The review determined that Biogen, the drug’s manufacturer, set “an unjustifiably high price” of $56k/year in an effort to make history and “establish Aduhelm as one of the top pharmaceutical launches of all time.” The investigation also revealed that Biogen budgeted several billion dollars to aggressively market and counter anticipated pushback against critics of its price. 

FDA warning letters surge - is your team prepared?
New guide reveals expert strategies to prevent regulatory issues and respond effectively to FDA enforcement actions in pharmaceutical and medical device manufacturing.
Read More
FDA warning letters surge - is your team prepared?
Medical Device Innovations Report
Cutting-edge packaging technologies are transforming the medical device sector in PMMI’s “Innovation in Medical Device” report, featuring advanced materials, smart solutions, and evolving regulations. Editors share insights from nearly 300 PACK EXPO booth visits—each product deemed new and truly innovative—alongside video demonstrations of the equipment and materials on display.
Learn More
Medical Device Innovations Report